Impact of carcinoma in situ on the outcome of intravesical Bacillus Calmette-Guérin therapy for non-muscle-invasive bladder cancer: a comparative analysis of large real-world data

[1]  H. Nishiyama,et al.  Non-maintenance intravesical Bacillus Calmette–Guérin induction therapy with eight doses in patients with high- or highest-risk non-muscle invasive bladder cancer: a retrospective non-randomized comparative study , 2021, BMC cancer.

[2]  C. Dinney,et al.  Revisiting an Old Conundrum: A Systematic Review and Meta-Analysis of Intravesical Therapy for Treatment of Urothelial Carcinoma of the Prostate , 2021, Bladder cancer.

[3]  G. Steinberg,et al.  Increased Bacillus Calmette-Guérin Treatment Intensity Associated With Improved Outcomes in Elderly Patients With Non-Muscle-Invasive Bladder Cancer in US Clinical Practice. , 2020, Urology.

[4]  T. Tsuzuki,et al.  Clinical Practice Guidelines for Bladder Cancer 2019 update by the Japanese Urological Association: Summary of the revision , 2020, International journal of urology : official journal of the Japanese Urological Association.

[5]  A. Kibel,et al.  Quantifying the Overall Survival Benefit With Early Radical Cystectomy for Patients With Histologically Confirmed T1 Non-muscle-invasive Bladder Cancer. , 2020, Clinical genitourinary cancer.

[6]  Shahrokh F. Shariat,et al.  European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update. , 2019, European urology.

[7]  Matthew P. Goetz,et al.  NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY , 2019 .

[8]  Siteng Chen,et al.  Maintenance versus non-maintenance intravesical Bacillus Calmette-Guerin instillation for non-muscle invasive bladder cancer: A systematic review and meta-analysis of randomized clinical trials. , 2018, International journal of surgery.

[9]  S. Selph,et al.  Intravesical Therapy for the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta‐Analysis , 2017, The Journal of urology.

[10]  L. Kiemeney,et al.  Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guérin: results of a retrospective multicenter study of 2451 patients. , 2015, European urology.

[11]  R. Sylvester,et al.  Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin. , 2012, European urology.

[12]  T. D. de Reijke,et al.  Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladd , 2010, European urology.

[13]  L. Martínez-Piñeiro,et al.  Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. , 2009, The Journal of urology.

[14]  Anirban P. Mitra,et al.  Superficial bladder cancer: an update on etiology, molecular development, classification, and natural history. , 2008, Reviews in urology.

[15]  L. Klotz,et al.  Urothelial carcinoma of the prostate. , 2007, Urology.

[16]  J Alfred Witjes,et al.  Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. , 2006, European urology.

[17]  P. Sogani,et al.  Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? , 2001, The Journal of urology.